Researchers at the Medical University of Vienna have uncovered how a little-studied protein, TRAT1 (T Cell Receptor ...

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...

Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...

Pilatus Biosciences Announces Issuance of Foundational Global Patent Covering Novel CD36-Targeted Immunotherapy ...

Preclinical data support Abalos’ first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to treat solid tumors -- Düsseldorf, Germany, October 14 ...

Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio ...

CRISPR-based tools can’t easily access the DNA in these organelles, but researchers are finding other ways in.

T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

胰腺癌（Pancreatic Cancer）以胰腺导管腺癌（PDAC）最为常见，具有起病隐匿、早期转移、对化疗/免疫治疗敏感性差的特点，长期总体生存率低，仍是肿瘤学中预后最差的实体瘤之一。

Sana Biotechnology, Inc. is a Strong Buy with promising cell therapies for diabetes & B-cell disorders. Click here to find ...